Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD).
According to Clearmind, this expansion follows the recent enrollment of the trial’s first patient, announced on June 5, 2025, marking a significant milestone in the development of CMND-100. Dr. David Zeltser, director of the Emergency Medicine Department, will lead the study at TASMC, joining other prestigious institutions participating in the trial, including Yale School of Medicine’s Department of Psychiatry, and Johns Hopkins University School of Medicine in the U.S.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented, “We are pleased to welcome Tel Aviv Sourasky Medical Center to our Phase 1/2a clinical trial, alongside esteemed partners like Yale and Johns Hopkins. The enrollment of our first patient earlier this month was a pivotal moment, and expanding our clinical trial to additional leading clinical sites like TASMC underscores our commitment to addressing the global burden of AUD, which affects millions and accounts for 2.6 million deaths annually.”
